Our Plan and Approach
Commitment to Innovation
We are a startup pharmaceutical company that is positioned to introduce the first new innovation in injectable benzodiazepines in over 30 years.
Benzodiazepines, which are used to relax and sedate patients, were developed between 1960 and 1990, but little innovation in the development of new intramuscular drugs or delivery methods has taken place since then. Sollievo’s proprietary approach maintains safety while providing rapid absorption and sedation.
Being Market Disrupters
Sollievo Pharmaceuticals is well positioned to disrupt the $2.2 million global acute aggression and seizure markets, with the introduction of one of the fastest acting intramuscular benzodiazepine– Proviza ®